NCT03236233 is a Phase 1 clinical trial of PC786 - Single doses in Respiratory Syncytial Virus (RSV), sponsored by Pulmocide Ltd.

Who is sponsoring NCT03236233?

NCT03236233 is sponsored by Pulmocide Ltd.

What drugs are being tested in NCT03236233?

Interventions in NCT03236233: PC786 - Single doses, Placebo - Single doses, PC786 - Repeat doses, Placebo - Repeat doses.

What condition does NCT03236233 study?

NCT03236233 studies Respiratory Syncytial Virus (RSV).

Is NCT03236233 still recruiting?

NCT03236233 is currently completed. Last updated 21 December 2017.

Last reviewed 2017-12-21 · How we verify

NCT03236233

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786

Completed Phase 1 Last updated 21 December 2017

What this trial tests

Phase 1 trial testing PC786 - Single doses in Respiratory Syncytial Virus (RSV) in 39 participants. Completed in 15 December 2017.

Timeline

21 June 2017

Primary endpoint
15 December 2017

15 December 2017

Quick facts

Lead sponsor	Pulmocide Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	39
Start date	21 June 2017
Primary completion	15 December 2017
Estimated completion	15 December 2017
Sites	1 location across United Kingdom

Drugs / interventions tested

PC786 - Single doses — full drug profile →
Placebo - Single doses — full drug profile →
PC786 - Repeat doses — full drug profile →
Placebo - Repeat doses — full drug profile →

Conditions studied

Respiratory Syncytial Virus (RSV) — all drugs for Respiratory Syncytial Virus (RSV) →

Sponsor

Pulmocide Ltd — full company profile →

Who can join

Adults 18 to 65, any sex, with Respiratory Syncytial Virus (RSV). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the safety, tolerability and pharmacokinetics of single and repeat doses of PC786.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.
DeVincenzo J, Cass L, Murray A, Woodward K, et al · · 2022 · cited 38× · PMID 33216113 · DOI 10.1093/infdis/jiaa716
Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.
Brookes DW, Coates M, Allen H, Daly L, et al · · 2018 · cited 31× · PMID 29579332 · DOI 10.1111/bph.14221

Verify or expand the search:

Other recruiting trials for Respiratory Syncytial Virus (RSV)

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
NCT06851806 — Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease · NA · recruiting
NCT07249320 — Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants · active not recruiting
NCT07272434 — Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) · Phase 3 · recruiting
NCT07106918 — A Clinical Trial of SIBP-A16 Injection in Healthy Adults · EARLY_PHASE1 · recruiting

Other Pulmocide Ltd trials

Trials by the same sponsor.

NCT05238116 — Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory · Phase 3 · terminated
NCT05037851 — A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transp · Phase 2 · completed
NCT03905447 — The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. · Phase 2 · terminated
NCT03870841 — The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis · Phase 2 · terminated
NCT03745196 — The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03236233 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pulmocide Ltd
Last refreshed: 21 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03236233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing